76 related articles for article (PubMed ID: 8384277)
1. [Penetration into bone and joint tissues of rabbits and in vitro antibacterial activity of tosufloxacin].
Yamashiro Y; Nunome M; Takahata M; Yasuda T
Jpn J Antibiot; 1993 Jan; 46(1):31-5. PubMed ID: 8384277
[TBL] [Abstract][Full Text] [Related]
2. [Studies on suppurative lesion and bone distribution of peroral antimicrobial agents (LAPC and TFLX) to experimental infected rabbits].
Tanaka M; Satoh T
Shigaku; 1990 Oct; 78(3):527-52. PubMed ID: 2134803
[TBL] [Abstract][Full Text] [Related]
3. [Antibacterial activity of tosufloxacin against fresh clinical isolates].
Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M
Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895
[TBL] [Abstract][Full Text] [Related]
4. Diffusion of tosufloxacin into prostatic tissue.
Uchibayashi T; Hisazumi H; Kanayama J; Kumano K
Chemotherapy; 1992; 38(3):150-4. PubMed ID: 1380905
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
[TBL] [Abstract][Full Text] [Related]
6. [Antimicrobial activities of tosufloxacin against recently obtained clinical isolates].
Ishihara R; Suzuki Y; Tanaka S; Fukayama S; Deguchi K; Oda S; Nakane Y; Fukumoto T
Jpn J Antibiot; 1996 Jul; 49(7):715-42. PubMed ID: 8828073
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation].
Mikamo H; Tanaka K; Watanabe K
Jpn J Antibiot; 2006 Dec; 59(6):468-73. PubMed ID: 17334064
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
[TBL] [Abstract][Full Text] [Related]
9. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance of clinical isolates of methicillin-resistant Staphylococcus aureus to aminoglycosides and fluoroquinolones.
Uete T; Matsuo K; Uete G
Jpn J Antibiot; 1992 Aug; 45(8):943-8. PubMed ID: 1433900
[TBL] [Abstract][Full Text] [Related]
11. [Morphological changes in penicillin-resistant Streptococcus pneumoniae and beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae after exposure to oral antibacterial agents].
Chiba N; Morozumi M; Ubukata K
Jpn J Antibiot; 2012 Oct; 65(5):323-34. PubMed ID: 23383434
[TBL] [Abstract][Full Text] [Related]
12. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
Kobayashi I; Matsuzaki K; Omika K; Hasegawa M; Sato Y
Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257
[TBL] [Abstract][Full Text] [Related]
13. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae].
Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J
Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis].
Sato H; Fukuda S; Inatomi M; Koide R; Uchida N; Kanda Y; Kiuchi Y; Oguchi K
Nippon Ganka Gakkai Zasshi; 1996 Jul; 100(7):513-9. PubMed ID: 8741334
[TBL] [Abstract][Full Text] [Related]
16. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
Boos M; Mayer S; Fischer A; Köhrer K; Scheuring S; Heisig P; Verhoef J; Fluit AC; Schmitz FJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):938-42. PubMed ID: 11181385
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
18. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
19. [Lomefloxacin concentration in human prostatic tissue following 3-day administration].
Morita M; Hatakeyama T; Suzuki K
Hinyokika Kiyo; 1993 Jan; 39(1):97-9. PubMed ID: 7681621
[TBL] [Abstract][Full Text] [Related]
20. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
Ridgway GL; O'Hare MD; Felmingham D; Grüneberg RN
Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
